Objective: To study the association between time in therapeutic range (TTR) during warfarin therapy and risk of dementia in a population-based cohort of incident atrial fibrillation (AF).
A trial fibrillation (AF) is the most common arrhythmia of clinical significance in adults and is expected to afflict 5.6 million adults in the United States by 2050. 1, 2 The prevalence of AF increases with age, and 45% of affected individuals are older than 75 years. 1 Atrial fibrillation is associated with a 40% increased risk of dementia independent of the occurrence of clinical stroke. 3, 4 Dementia, in turn, is an important cause of morbidity and mortality in the elderly and an enormous public health problem with a major impact from personal and socioeconomic standpoints. 5 Atrial fibrillation is associated with cerebral thromboembolism, a proposed mechanism by which AF may increase the risk of dementia. [6] [7] [8] Oral anticoagulation with warfarin is effective in preventing thromboembolism in AF, but its effect on risk of dementia is unknown. The efficacy of warfarin in preventing thromboembolism also depends on the intensity of anticoagulation as measured by the international normalized ratio (INR). Although subtherapeutic INR levels can increase the risk of cerebral thromboembolism, supratherapeutic INR levels can predispose to intracranial hemorrhage, both of which may increase the risk of cognitive decline. [9] [10] [11] The time in therapeutic range (TTR) is a measure of the efficacy of warfarin anticoagulation. The aim of this study was to assess the impact of warfarin anticoagulation and the TTR on the risk of dementia in a community-based cohort of incident AF.
METHODS

Study Population
This study was conducted in Olmsted County, Minnesota, where most health care is provided by Mayo Clinic, Olmsted Medical Center, and their affiliated hospitals. All health careerelated data were retrieved through the records linkage system of the Rochester Epidemiology Project. [12] [13] [14] This study was approved by the institutional review boards of Mayo Clinic and Olmsted Medical Center.
The study design and data retrieval are detailed previously. 15 Briefly, adults (aged !18 years) with AF or atrial flutter from January 1, 2000, through December 31, 2010, were identified using International Classification of Diseases, Ninth Revision (ICD-9) codes 427.31 and 427.32 or diagnosis of AF or atrial flutter on an electrocardiogram obtained at Mayo Clinic. Those with AF or atrial flutter diagnosed before 2000 were classified as having prevalent AF and were excluded. The medical records of the remaining patients were manually reviewed to validate incident AF if electrocardiographic evidence or a physician diagnosis was present. Patients with the only event of AF documented within 30 days of cardiothoracic surgery without any subsequent recurrence were considered to have postsurgical AF and were excluded.
Ascertainment of Clinical Data
Clinical data on comorbid conditions were obtained using ICD-9 codes from inpatient and outpatient encounters. We required at least 2 occurrences of a code (either the same code or different codes in the code set) in the 5 years before incident AF to validate the diagnosis. The list of diagnosis codes used to define each comorbidity can be found in the Supplemental Table (available online at http:// www.mayoclinicproceedings.org). Stroke risk was assessed by calculating the CHA 2 DS 2 -VASc (congestive heart failure, hypertension, age !75 years, diabetes mellitus, stroke/transient ischemic attack, vascular disease, age 65 to 74 years, sex category) score. 16 Smoking status, height, and weight were manually abstracted from the medical record at the time of incident AF. Body mass index was calculated as weight in kilograms divided by height in meters squared.
Diagnosis of Dementia
We used ICD-9 codes 290, 294.1, 294.8, 331.0-331.2, 331.7, and 331.82 to identify study participants diagnosed as having dementia based on previously validated codes. 17 If the diagnosis of dementia was first established before or within 6 months of diagnosis of AF, it was considered prevalent dementia and the individual was excluded.
Time in Therapeutic Range
International normalized ratio measurements were obtained to determine patients who were prescribed warfarin and to calculate the TTR for warfarin. All patients in the county had their INR measured at 1 of 2 hospitals, providing a complete record of their INRs. Most patients in the county are managed at anticoagulation clinics that use a standard protocol for warfarin dose adjustment, although the site of anticoagulation management for individual patients in the cohort is not available. Patients with all INRs less than 1.5 were considered to have never been taking warfarin. When a gap of more than 90 days between consecutive INR measurements was observed, we assumed that warfarin was discontinued. When warfarin was initiated (or reinitiated after a gap), INRs obtained within the first 7 days were excluded. When multiple INRs were measured on the same day, the mean value was used for that day. An INR was calculated for each day during follow-up using linear interpolation for the days between INR measurements. 18 
Statistical Analyses
Characteristics of the patients at the time of AF diagnosis are described as mean AE SD for normally distributed continuous variables, median (25th-75th percentile) for nonnormally distributed continuous variables, and number (percentage) for categorical variables. Logistic regression was used to test for differences in patient characteristics for those who initiated warfarin therapy within the first 90 days of follow-up and those not taking warfarin in the first 90 days. Cox proportional hazards regression models were used to estimate the risk of dementia for those with vs without warfarin use within the first 90 days after AF diagnosis. Unadjusted, age-and sex-adjusted, and fully adjusted models adjusting for age, sex, body mass index, history of smoking, hypertension, hyperlipidemia, diabetes, heart failure, ischemic stroke/transient ischemic attack (TIA), hemorrhagic stroke, myocardial infarction, peripheral vascular disease, aortic atherosclerotic disease, chronic pulmonary disease, malignancy, liver disease, and renal disease were modeled (adjusted model 1). In addition, development of ischemic stroke/TIA or hemorrhagic stroke during follow-up was added as a time-dependent variable to the fully adjusted model (adjusted model 2). The percentage of TTR was calculated for each patient as the ratio of the number of days the INR was between 2 and 3 to the total number of days receiving warfarin. Kaplan-Meier survival curves were plotted by quartiles of percentage of TTR. Cox models were run with quartiles of percentage of TTR as the exposure (with patients never taking warfarin serving as the reference group). Finally, for each day a patient was taking warfarin, the INR was categorized as subtherapeutic (INR, <2), therapeutic (INR, 2-3), or supratherapeutic (INR, >3). For each period of warfarin use, the percentage of time spent in each INR category was calculated. In the Cox models, warfarin use and percentage of time spent in the subtherapeutic, therapeutic, and supratherapeutic range were modeled as time-dependent variables, with no warfarin as the referent.
RESULTS
Study Population and Warfarin Use
A new diagnosis of AF was determined in 3344 individuals from January 1, 2000, through December 31, 2010, in Olmsted County. Of these individuals, 544 (16.3%) were excluded due to prevalent dementia (n¼319), dementia diagnosis within 6 months of AF (n¼86), and incomplete data (n¼139). The study cohort consisted of 2800 individuals with a mean AE SD age of 71.2AE14.6 years; 53.4% were men (n¼1495) and 97.0% were white (n¼2716). The CHA 2 DS 2 -VASc score was 0, 1, 2, and greater than 2 in 9.8%, 11.8%, 15.0%, and 63.4% of patients, respectively. Overall, 1414 patients (50.5%) were initiated on warfarin within 90 days of the diagnosis of AF, and 1772 (63.3%) were taking warfarin at some point during the study. Only 51 patients (1.8%) were taking a novel direct oral anticoagulant (dabigatran, apixaban, or rivaroxaban) during follow-up after 2011. The use of these novel anticoagulants was not considered in the analysis due to the small proportion of patients taking these agents. The baseline clinical characteristics of the whole cohort and stratified by warfarin therapy within 90 days of AF diagnosis are presented in Table 1 . Patients initiated on warfarin were older and were more likely to have hypertension, diabetes mellitus, hyperlipidemia, myocardial infarction, and stroke or TIA at the time of AF diagnosis. Of the patients with CHA 2 DS 2 -VASc scores of 2 or greater, the level of risk for which anticoagulation is generally recommended, 1178 of 2196 (53.6%) were initiated on warfarin within 90 days after AF diagnosis; warfarin was initiated in 236 of 604 patients with AF (39.1%) with CHA 2 DS 2 -VASc scores less than 2.
Warfarin Therapy and Dementia in AF During mean AE SD follow-up of 5.0AE3.7 years, dementia was diagnosed in 357 patients (12.8%) 6 months or more after the diagnosis of AF. The cumulative incidence (95% CI) of dementia at 2 and 5 years was 4.4% (3.5%-5.2%) and 11.6% (10.2%-13.0%), respectively. The incidence (95% CI) of dementia in the group with warfarin therapy within 90 days after AF diagnosis was 4.1% (3.0%-5.3%) and 11.2% (9.2%-13.1%) at 2 and 5 years, respectively. Dementia was diagnosed in 4.6% (95% CI, 3.4%-5.9%) and 12.1% (95% CI, 9.9%-14.1%) of patients without warfarin within 90 days at 2 and 5 years, respectively (P¼.58 comparing the incidence of dementia for those with and without warfarin therapy within 90 days). The associations between warfarin therapy within 90 days after AF and dementia in unadjusted and adjusted models are presented in (43.0%) remained on warfarin throughout follow-up, 436 (24.6%) discontinued warfarin use and never resumed, 397 (22.4%) discontinued warfarin and resumed use at least once and were on warfarin at the time of dementia/last follow-up, and 177 (10.0%) discontinued warfarin and resumed use at least once and were not receiving warfarin at the time of dementia/last follow-up. The mean AE SD percentage of TTR was 52.2%AE26.4%. To assess the possible effect of preexisting cognitive decline on percentage of TTR, we also examined the percentage of TTR within 1 year before the diagnosis of dementia. In patients who developed dementia, the mean AE SD percentage of TTR within 1 year before dementia diagnosis (51.6%AE26.5%) was lower than that more than 1 year before dementia (52.2%AE24.8%) and was also lower than the percentage of TTR in patients without dementia (52.5%AE26.7%). However, the absolute differences in the percentage of TTR noted previously herein may not be clinically meaningful.
Patients were divided into quartiles of percentage of TTR (quartile 1: 0%-36.03%; quartile 2: 36.04%-59.50%; quartile 3: 59.51%-71.93%; quartile 4: 71.94%-100%), and the incidence of dementia was examined in each quartile. Mean AE SD percentage of TTR in each quartile was 12.8%AE12.7%, 49.6% AE 6.9%, 66.2% AE3.7%, and 80.0% AE 6.5%, respectively. The Figure presents survival free of dementia in each quartile of percentage of TTR. Compared with the group without warfarin therapy, quartiles 3 and 4 for percentage of TTR were associated with a 46% and 72% reduced risk of dementia, respectively, in the fully adjusted model 2 (Table 3 ). In contrast, quartiles 1 and 2 of percentage of TTR had similar risk of dementia compared with those not treated with warfarin.
We performed additional modeling to determine the impact of percentage of time spent in subtherapeutic, therapeutic, and supratherapeutic ranges on dementia risk. Combining the daily INR results during follow-up for all patients, the cohort receiving warfarin spent 19%, 67%, and 14% of their time taking warfarin in the subtherapeutic, therapeutic, and supratherapeutic ranges, respectively. These proportions were considered the referent. Modeling warfarin use and percentage of time in the subtherapeutic, therapeutic, and supratherapeutic ranges as timedependent variables, the unadjusted and adjusted models are presented in Table 4 . A 10% absolute increase in the percentage of TTR was associated with a significant decrease in the risk of dementia. The risk reduction was comparable if the increase in the percentage of TTR occurred in conjunction with a reduction in the percentage of time spent in the supratherapeutic range (model 2: HR, 0.67; 95% CI, 0.57-0.79) or the subtherapeutic range (HR, 0.71; 95% CI, 0.64-0.79).
DISCUSSION
In a population-based cohort of patients with incident AF, anticoagulation with warfarin was associated with an approximately 20% lower risk of dementia. In patients who start taking warfarin, greater efficacy of warfarin anticoagulation, measured by the TTR, was significantly associated with lower risk of dementia. Only those in the 2 highest quartiles of percentage of TTR had an associated decline in the risk of dementia. The incidence of dementia in patients with TTR below the median was similar to that in patients not prescribed warfarin. Increased TTR as a result of decreased time spent in both subtherapeutic and supratherapeutic INR was associated with a reduction in the incidence of dementia. The mechanisms of cognitive impairment in AF are likely multifactorial. A role for cerebral infarcts due to thromboembolism and cerebral hypoperfusion due to reduced cardiac output has been proposed. 6, 7, 19 Most cerebral infarcts detected by magnetic resonance imaging (MRI) do not manifest as clinical stroke. These silent cerebral infarcts have been associated with higher risk of cognitive impairment and dementia in the general population and in patients with AF. 6, 7, 20 Graff-Radford et al 7 reported a 30% prevalence of MRI-detected cerebral infarct in community-dwelling individuals with AF, a significantly higher prevalence compared with those without AF (odds ratio, 1.87; 95% CI, 1.25-2.81). The risk of cognitive Adjusted for age, sex, body mass index, history of smoking, hypertension, hyperlipidemia, diabetes, heart failure, ischemic stroke/transient ischemic attack, hemorrhagic stroke, myocardial infarction, peripheral vascular disease, aortic atherosclerotic disease, chronic pulmonary disease, malignancy, liver disease, and renal disease. impairment in patients with AF with MRI evidence of infarction was 3 times higher than that in patients with AF without cerebral infarct and patients without AF. 7 Barber et al 21 reported serum markers of increased thrombin generation and fibrin turnover in individuals with AF who developed dementia, suggestive of a predisposition for thrombosis. Oral anticoagulation with warfarin has been shown to reduce the incidence of thromboembolism and stroke in AF 22 and is a potential mechanism for the reduction in risk of dementia associated with anticoagulation that we observed in this study. We also observed that the effect of warfarin therapy on dementia was more pronounced in those with CHA 2 DS 2 -VASc scores of 2 or greater, a subset with higher risk of thromboembolism for whom anticoagulation is recommended by guideline. 16 Warfarin has a narrow therapeutic window for the prevention of stroke, with the greatest efficacy and safety when INR is maintained between 2 and 3. There is a 5-fold increased risk of ischemic stroke with INR less than 2 and a 3-fold increased risk of major bleeding with INR greater than 3. 9 The risk of stroke, myocardial infarction, major bleeding, and death increases on a continuum with the decline in TTR. 9, 23, 24 The present study suggests that the benefits of maintaining INR in the therapeutic range of 2 to 3 may extend beyond stroke prevention to better neurocognitive outcomes. However, due to the observational design of the study, conclusions regarding cause and effect cannot be drawn, and these findings are hypothesis generating only. The novel direct oral anticoagulants may provide a more steady state of anticoagulation, thus theoretically avoiding the fluctuations in anticoagulation intensity associated with warfarin. Whether this translates to reduced risk of cognitive impairment in patients treated with a novel anticoagulant requires future prospective study. Due to the time frame of the present study, the use of these novel anticoagulants was not prevalent.
Prevention of thromboembolism can potentially explain the reduction in incident dementia in association with a reduction in subtherapeutic INR. A striking finding, however, is the reduction in dementia risk noted with decline in time spent in supratherapeutic INR. Warfarin anticoagulation is associated with increased risk of intracerebral hemorrhage, with a progressive increase with every 0.5 elevation in INR. 25 Clinically manifest intracerebral hemorrhage is associated with an increased risk of cognitive decline, but the incidence is low even in anticoagulated patients. 10, 11 Cerebral microbleeds, which are associated with amyloid angiopathy and arteriolosclerosis, have emerged as a predictor of future intracerebral hemorrhage and cognitive decline. [26] [27] [28] Both AF and oral anticoagulation have been associated with an increased prevalence of cerebral microbleeds. 29, 30 Although cerebral microbleeds are more likely to occur in those treated with an anticoagulant, microbleeds, in turn, increase the risk of warfarinassociated cerebral hemorrhage. 26, 28, 31, 32 The presence of cerebral microbleeds and hemorrhage may be a potential explanation for the elevated risk of dementia with supratherapeutic anticoagulation. It is possible that at a threshold INR of 3, the risk of dementia in association with cerebral bleed may outweigh any benefit from prevention of thromboembolism. Neuroimaging was, however, not performed as part of this study, and this hypothesis should be verified in future studies.
This study presents the first comprehensive longitudinal study on risk of dementia in patients with AF with and without oral anticoagulation in a community setting and adds to previous reports. Barber et al 21 reported a trend toward a reduced incidence of dementia in patients with AF treated with warfarin. In contrast, the Birmingham Atrial Fibrillation Treatment of the Aged Study, a randomized controlled trial of warfarin vs aspirin in AF, did not show a significant difference in Mini-Mental State Examination scores between the groups, although a trend in favor of warfarin was noted at 33 months. 33 Both studies were limited by smaller sample size and shorter follow-up. Jacobs et al 34 reported an increasing incidence of dementia with lower TTR in a cohort of warfarintreated patients with AF. In contrast to the present study, however, there was no differential effect of subtherapeutic and supratherapeutic INR on incident dementia. An increased incidence of dementia in patients with AF with supratherapeutic INR and combination therapy with an antiplatelet agent has been reported. 35 Only 64% of patients in the cohort were administered warfarin, which is comparable to data from national registries that show less than two-thirds of eligible patients with AF are receiving anticoagulation. 36 In the present study, the TTR is lower than that reported in randomized controlled trials of anticoagulation in AF but comparable to that in multiple other observational studies and represents real-world experience and also illustrates the potential for improvement. 24, 37, 38 Challenges to maintaining therapeutic INR are frequently multifactorial, and the impact of novel oral anticoagulants on cognitive outcomes warrants investigation.
This study has several limitations. This is an observational study, and the decision to treat with warfarin was not randomized. Although known confounders were adjusted for, residual confounding due to unmeasured risk factors such as alcohol consumption cannot be excluded. The duration, pattern (paroxysmal vs persistent), and treatment (rate vs rhythm control) of AF could not be reliably determined and may affect the risk of dementia and the decision to anticoagulate. Factors beyond the risk of stroke can influence the prescription of anticoagulants, including the diagnosis of dementia, risk of falls, and nursing home residence. 39, 40 Cognitive impairment represents a continuous spectrum of disorders, and patients with milder forms of the disease may remain undiagnosed. Patients with cognitive impairment may have a lower rate of initiation and a higher rate of discontinuation of oral anticoagulant therapy. Discontinuation of warfarin use could not be definitely determined in this cohort. Anticoagulated patients with mild cognitive impairment may also have lower TTR due to medication noncompliance and inability to follow dietary restrictions, which may influence the observations of this study. The exclusion of patients with prevalent dementia and incident dementia within 6 months of AF diagnosis reduces this bias but does not eliminate the possibility of undiagnosed milder forms of cognitive dysfunction, affecting prescription patterns or the TTR. The TTR in the year before dementia diagnosis was noted to be slightly lower than that in the preceding years, but the absolute difference may not be clinically significant. However, the TTR greater than 1 year before the diagnosis of dementia was comparable to that of individuals who did not develop dementia, suggesting that undiagnosed dementia likely did not have a significant effect on most INR measurements obtained in the study.
Patients prescribed warfarin had more comorbidities than those not prescribed warfarin, many of which have been known to affect the risk of dementia. Although statistical methods to adjust for these confounders were undertaken, we cannot rule out the possibility of residual confounding resulting in a more conservative estimate of the association between warfarin use and dementia.
The reason for the prescription of oral anticoagulation was not available, and indications other than AF cannot be excluded, especially in lower-risk patients with CHA 2 DS 2 -VASc scores less than 2. Standardized neurocognitive testing to establish the diagnosis of dementia was not performed and dementia may be underdiagnosed. The use of over-the-counter drugs such as aspirin and nonsteroidal antiinflammatory drugs could not be ascertained and may affect the outcome. Finally, INR values vary from day to day, and the use of linear interpolation between 2 measurements may not accurately reflect these day-to-day variations in the intensity of anticoagulation.
CONCLUSION
Oral anticoagulation with warfarin was associated with a reduced incidence of dementia in a community-based cohort of incident AF, with a more prominent effect in those with CHA 2 DS 2 -VASc scores of 2 or greater. These data support and extend the potential benefits of current recommendations to anticoagulate high-risk patients with AF. Furthermore, in patients taking warfarin, more time in the narrow therapeutic window of warfarin was associated with a reduced risk of dementia compared with patients with less TTR. Because novel direct oral anticoagulants are associated with less variations in the intensity of anticoagulation, prospective studies on the role of warfarin and the novel oral anticoagulants in preventing cognitive decline in patients with are needed.
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